Tarsa Therapeutics

Tarsa Therapeutics is focused on developing innovative therapies for postmenopausal osteoporosis, addressing significant unmet medical needs in the women's health sector with their flagship product, TBRIA™. Founded in 2009 in Philadelphia, US, Tarsa Therapeutics specializes in therapies for postmenopausal osteoporosis. The company has raised USD 7. 00 mn across multiple funding rounds, with the most recent being a VENTURE DEBT financing round in August 2014, where they secured USD 10.

00 mn from Oxford Finance Corporation and Square 1 Bank. The company is led by CEO David Brand. Tarsa Therapeutics develops TBRIA™, an oral formulation of calcitonin specifically designed for women post-menopause. This product aims to provide an effective treatment option for those for whom alternative therapies are unsuitable.

TBRIA has undergone clinical validation through the global Phase 3 ORACAL trial, targeting healthcare professionals and institutions involved in osteoporosis treatment, particularly in regions with high prevalence of the condition among postmenopausal women. Tarsa Therapeutics generates revenue through strategic partnerships and licensing agreements, particularly with R-Pharm JSC, which has acquired rights for further clinical development and regulatory submissions for TBRIA. The company's revenue model focuses on B2B transactions, supplying healthcare institutions and providers with TBRIA for osteoporosis management. With the recent VENTURE DEBT financing of USD 10.

00 mn raised in August 2014, Tarsa Therapeutics aims to enhance its clinical development strategies. The company is focused on expanding TBRIA's market reach, particularly targeting regions with high rates of postmenopausal osteoporosis. Future initiatives include upcoming new products that build on the existing portfolio, although specific release dates are yet to be disclosed.